


TRANSCENDING MECHANICAL SOLUTIONS FOR DIALYSIS ACCESS



GORE® PROPATEN®
Vascular Graft

Together, improving life




Clinical experience

Significant 20% improvement in clot-free survival as compared to the control group.

— *Ingemar Davidson, M.D.*¹

UT Southwestern Dallas, Texas



[GORE® PROPATEN® Vascular Graft] may have a better primary and secondary patency rate and lower thrombosis rate compared with standard ePTFE.

— *David Shemesh, M.D.*,²
Shaare Zedek Medical Center, Jerusalem, Israel

Study results

	Standard ePTFE n = 29	GORE® PROPATEN® Vascular Graft n = 24
n	29	24
Thrombosis n	11 (38%)	5 (21%)
Interventions n	19	8
Interventions per patient year	2.6	0.8

* Clot-free survival is defined as grafts without thrombosis

Addressing vascular graft failure modes


Thrombosis

The bioactive luminal surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft remains free of thrombus, while the non-bioactive surface of a control graft (3 mm diameter) is covered with thrombus. Grafts were explanted after two hours in a challenging carotid shunt canine model.

— Begovac, et al.³



GORE® PROPATEN® Vascular Graft




Control ePTFE graft


Intimal hyperplasia

Neointimal hyperplasia at the distal anastomoses of an aortoiliac bypass graft model in baboons. Statistically significant reduction in neointimal hyperplasia at the distal anastomosis was observed for the GORE® PROPATEN® Vascular Graft as compared to untreated control ePTFE.

— Lin, et al.⁴




GORE® PROPATEN® Vascular Graft



Control ePTFE graft

A: Distal anastomosis of untreated control ePTFE graft **B:** Distal anastomosis of the GORE® PROPATEN® Vascular Graft. **L:** Lumen; **N:** Neointima; **G:** ePTFE Graft. Collagens are blue, elastin is black, others are red. (Verhoeff-Masson stain; original magnification X40) Images reproduced with permission from Elsevier.

Proprietary end-point covalent bonding



Selected literature

- 1 Davidson I, Hackerman C, Kapadia A, Minhajuddin A. Heparin bonded hemodialysis e-PTFE grafts result in 20% clot free survival benefit. *Journal of Vascular Access* 2009;10(3):153-156.
- 2 Shemesh D, Goldin I, Zaghal I, Berelowitz D, Verstandig A, Olsha O. Heparin-bonded graft (PROPATEN®) versus standard graft in prosthetic arteriovenous access. Abstract presented at the 6th International Congress of the Vascular Access Society (VAS); April 20-22, 2009; Rome, Italy. *Journal of Vascular Access* 2009;10(2):100-101.
- 3 Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® bioactive surface heparin immobilization. *European Journal of Vascular & Endovascular Surgery* 2003;25(5):432-437.
- 4 Lin PH, Chen C, Bush RL, Yao Q, Lumsden AB, Hanson SR. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. *Journal of Vascular Surgery* 2004;39(6):1322-1328.

 Consult Instructions
for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

Products listed may not be available in all markets.

GORE, *Together, improving life*, PROPATEN and designs are trademarks of W. L. Gore & Associates.
© 2023 W. L. Gore & Associates GmbH 23952205-EN MARCH 2023

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

